Also important to recognize is why developing countries are unable to represent a suitable market to pharmaceutical companies. Many of the billions of people that would benefit from drugs for preventable diseases live on less than $1 a day, and nearly all that would benefit live on less than $2 a day. When basic sustenance is difficult to achieve, it is hardly likely that there will be sufficient out-of-pocket funds for vaccinations.
Also significant is that measures such as this fail to get at some of the core issues that create the problem in the first place. Issues such as for-profit medicine, which bring about the terrifying 10:90 divide: where 90% of investment in pharmaceuticals is directed toward diseases that affect only 10% of people in the world. Of course, this 10% are the wealthiest. This frightening discrepancy between those who need and those who have only shows further the moral bankruptcy under which we exist. This is an industry where the majority of products released are knock-off drugs that are about to lose their patent or drugs that closely emulate products put out by their competitors. A more democratic form of research and development of pharmaceuticals would be extremely beneficial worldwide. It seems the only people that are benefitting from the increasing concentration of pharmaceutical companies are those companies themselves. When large parts of the research are carried out in public universities, it makes it difficult to identify what role these pharmaceutical companies are really playing in facilitating a more healthy world.